Home › Companies › Gyre Therapeutics, Inc. › 2025-2026
At Gyre Therapeutics, Inc.'s shareholder meeting held June 10, 2026, in the 2025-2026 proxy season, 83 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 432 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of the Company's named executive… — Gyre Therapeutics, Inc.'s filing reports the proposal as approved, with 99.9% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Gyre Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 16, 2026.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Gyre Therapeutics, Inc.’s Form 8-K, filed June 16, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 10, 2026: 5 items on Gyre Therapeutics, Inc.’s Form 8-K, filed June 16, 2026: 2 elected · 3 approved.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2024-2025 2025-2026
Explore Gyre Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Gyre Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 16, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: David M. Epstein, Ph.D. | 70,160,332 | -- | -- | 354,109 | 1,985,197 | 99.4% | Elected | — |
| Elect Director: Dan Weng, M.D. | 70,483,425 | -- | -- | 31,016 | 1,985,197 | 99.9% | Elected | — |
| 2. Non-Binding Advisory Vote on Executive Compensation The compensation of the Company's named executive officers | 70,478,374 | 34,907 | 1,160 | -- | 1,985,197 | 99.9% | Approved | — |
| 3. Ratification of Independent Auditor The appointment of Grant Thornton Zhitong Certified Public Accountants LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 | 72,487,596 | 11,626 | 416 | -- | 0 | 99.9% | Approved | — |
| 4. Approval of Conversion of Series B Preferred Stock The issuance of shares of the Company's common stock, par value $0.001 per share, upon conversion of the Company's Series B Convertible Preferred Stock, par value $0.001 per share | 70,497,125 | 16,031 | 1,285 | -- | 1,985,197 | 99.9% | Approved | — |
Source: Gyre Therapeutics, Inc., Form 8-K, filed with the SEC on June 16, 2026 — read the filing on EDGAR.
Each item below shows how the 83 asset managers that disclosed a Gyre Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: Election of Class II Directors for terms expiring in 2029: Dan Weng, M.D.
Gyre Therapeutics, Inc.’s own tally for this item (“Elect Director: Dan Weng, M.D.”): 70,483,425 for, 31,016 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, each of the Company's director nominees was elected and the other proposals voted on were approved.”
Support: 99.9% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 33 asset managers below reported 1,010,939 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 532,566 | 0 | 0 | 0 | For |
| Fidelity | 182,213 | 0 | 0 | 0 | For |
| BlackRock | 153,546 | 0 | 0 | 0 | For |
| Charles Schwab | 60,096 | 0 | 0 | 0 | For |
| WisdomTree | 20,090 | 0 | 0 | 0 | For |
| Equitable | 16,142 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 9,244 | 0 | 0 | 0 | For |
| Pacific Life | 5,664 | 0 | 0 | 0 | For |
| Global X | 5,633 | 0 | 0 | 0 | For |
| Lincoln Financial | 5,500 | 0 | 0 | 0 | For |
| Northern Trust | 2,500 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 2,488 | 0 | 0 | 0 | For |
| SEI | 2,000 | 0 | 0 | 0 | For |
| ProShares | 1,534 | 0 | 0 | 0 | For |
| Goldman Sachs | 1,469 | 0 | 0 | 0 | For |
| Voya | 1,463 | 0 | 0 | 0 | For |
| GPS Funds I | 1,313 | 0 | 0 | 0 | For |
| Venerable Variable Insurance Trust | 1,124 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 1,063 | 0 | 0 | 0 | For |
| Principal | 887 | 0 | 0 | 0 | For |
| DWS | 880 | 0 | 0 | 0 | For |
| Calvert | 683 | 0 | 0 | 0 | For |
| State Street | 552 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 500 | 0 | 0 | 0 | For |
| American Century | 477 | 0 | 0 | 0 | For |
Showing the 25 largest of 33 asset managers. All 33 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99.4% Majority: yes · of votes cast
Description as filed by funds: Election of Class II Directors for terms expiring in 2029: David M. Epstein, Ph.D.
Gyre Therapeutics, Inc.’s own tally for this item (“Elect Director: David M. Epstein, Ph.D.”): 70,160,332 for, 354,109 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, each of the Company's director nominees was elected and the other proposals voted on were approved.”
Support: 99.4% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 33 asset managers below reported 822,793 for, 22,864 withheld, 165,282 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 532,562 | 0 | 4 | 0 | For |
| Fidelity | 182,213 | 0 | 0 | 0 | For |
| BlackRock | 0 | 0 | 153,546 | 0 | Abstain |
| Charles Schwab | 60,096 | 0 | 0 | 0 | For |
| WisdomTree | 20,090 | 0 | 0 | 0 | For |
| Equitable | 0 | 0 | 0 | 16,142 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 9,244 | 0 | Abstain |
| Pacific Life | 0 | 0 | 0 | 5,664 | Withhold |
| Global X | 5,633 | 0 | 0 | 0 | For |
| Lincoln Financial | 5,500 | 0 | 0 | 0 | For |
| Northern Trust | 2,500 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 0 | 0 | 2,488 | 0 | Abstain |
| SEI | 2,000 | 0 | 0 | 0 | For |
| ProShares | 1,534 | 0 | 0 | 0 | For |
| Goldman Sachs | 1,469 | 0 | 0 | 0 | For |
| Voya | 1,463 | 0 | 0 | 0 | For |
| GPS Funds I | 1,313 | 0 | 0 | 0 | For |
| Venerable Variable Insurance Trust | 1,124 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 1,063 | 0 | 0 | 0 | For |
| Principal | 887 | 0 | 0 | 0 | For |
| DWS | 880 | 0 | 0 | 0 | For |
| Calvert | 0 | 0 | 0 | 683 | Withhold |
| State Street | 552 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 500 | 0 | 0 | 0 | For |
| American Century | 477 | 0 | 0 | 0 | For |
Showing the 25 largest of 33 asset managers. All 33 are in the interactive database (link above).
99.9% Approved · of votes cast
Description as filed by funds: TO APPROVE, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(A), THE ISSUANCE OF SHARES OF THE COMPANY'S COMMON STOCK, PAR VALUE $0.001 PER SHARE, UPON CONVERSION OF THE COMPANY'S SERIES B CONVERTIBLE PREFERRED STOCK, PAR VALUE $0.001 PER SHARE.
Gyre Therapeutics, Inc.’s own tally for this item (“4. Approval of Conversion of Series B Preferred Stock The issuance of shares of the Company's common stock, par value $0.001 per share, upon conversion of the Company's Series B Convertible Preferred Stock, par value $0.”): 70,497,125 for, 16,031 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 4: Approval of Conversion of Series B Preferred Stock The issuance of shares of the Company's common stock, par value $0.001 per share, upon conversion of the Company's Series B Convertible Preferred Stock, par value $0.001 per share, was approved, in accordance with Nasdaq Listing Rule 56…”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 33 asset managers below reported 1,010,939 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 532,566 | 0 | 0 | 0 | For |
| Fidelity | 182,213 | 0 | 0 | 0 | For |
| BlackRock | 153,546 | 0 | 0 | 0 | For |
| Charles Schwab | 60,096 | 0 | 0 | 0 | For |
| WisdomTree | 20,090 | 0 | 0 | 0 | For |
| Equitable | 16,142 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 9,244 | 0 | 0 | 0 | For |
| Pacific Life | 5,664 | 0 | 0 | 0 | For |
| Global X | 5,633 | 0 | 0 | 0 | For |
| Lincoln Financial | 5,500 | 0 | 0 | 0 | For |
| Northern Trust | 2,500 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 2,488 | 0 | 0 | 0 | For |
| SEI | 2,000 | 0 | 0 | 0 | For |
| ProShares | 1,534 | 0 | 0 | 0 | For |
| Goldman Sachs | 1,469 | 0 | 0 | 0 | For |
| Voya | 1,463 | 0 | 0 | 0 | For |
| GPS Funds I | 1,313 | 0 | 0 | 0 | For |
| Venerable Variable Insurance Trust | 1,124 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 1,063 | 0 | 0 | 0 | For |
| Principal | 887 | 0 | 0 | 0 | For |
| DWS | 880 | 0 | 0 | 0 | For |
| Calvert | 683 | 0 | 0 | 0 | For |
| State Street | 552 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 500 | 0 | 0 | 0 | For |
| American Century | 477 | 0 | 0 | 0 | For |
Showing the 25 largest of 33 asset managers. All 33 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.
Gyre Therapeutics, Inc.’s own tally for this item (“2. Non-Binding Advisory Vote on Executive Compensation The compensation of the Company's named executive officers”): 70,478,374 for, 34,907 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2: Non-Binding Advisory Vote on Executive Compensation The compensation of the Company's named executive officers was approved, on a non-binding, advisory basis, as follows:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 532,566 | 0 | 0 | 0 | For |
| Fidelity | 182,213 | 0 | 0 | 0 | For |
| BlackRock | 153,546 | 0 | 0 | 0 | For |
| Charles Schwab | 60,096 | 0 | 0 | 0 | For |
| WisdomTree | 20,090 | 0 | 0 | 0 | For |
| Equitable | 16,142 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 9,244 | 0 | 0 | 0 | For |
| Pacific Life | 5,664 | 0 | 0 | 0 | For |
| Global X | 5,633 | 0 | 0 | 0 | For |
| Lincoln Financial | 5,500 | 0 | 0 | 0 | For |
| Northern Trust | 2,500 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 2,488 | 0 | 0 | 0 | For |
| SEI | 2,000 | 0 | 0 | 0 | For |
| ProShares | 1,534 | 0 | 0 | 0 | For |
| Goldman Sachs | 1,469 | 0 | 0 | 0 | For |
| Voya | 1,463 | 0 | 0 | 0 | For |
| GPS Funds I | 1,313 | 0 | 0 | 0 | For |
| Venerable Variable Insurance Trust | 1,124 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 1,063 | 0 | 0 | 0 | For |
| Principal | 887 | 0 | 0 | 0 | For |
| DWS | 880 | 0 | 0 | 0 | For |
| Calvert | 683 | 0 | 0 | 0 | For |
| State Street | 552 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 500 | 0 | 0 | 0 | For |
| American Century | 0 | 477 | 0 | 0 | Against |
Fund voting reports, all 33 managers: 1,010,370 for, 569 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 247,914 | 0 | 0 | 0 | For |
| BlackRock | 139,121 | 9,906 | 0 | 0 | Mixed |
| PNC BANK, NATIONAL ASSOCIATION | 94,000 | 0 | 0 | 0 | For |
| State Street | 74,146 | 3,133 | 0 | 0 | For |
| Northern Trust | 72,511 | 0 | 0 | 0 | For |
| Charles Schwab | 60,110 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 33,393 | 0 | 0 | 0 | For |
| AllianceBernstein | 21,830 | 0 | 0 | 0 | For |
| STRS OHIO | 21,100 | 0 | 0 | 0 | For |
| Vanguard | 19,146 | 0 | 0 | 0 | For |
| Fidelity | 18,438 | 0 | 0 | 0 | For |
| Goldman Sachs | 10,289 | 0 | 0 | 0 | For |
| JPMorgan | 4,800 | 0 | 0 | 0 | For |
| STATE OF WISCONSIN INVESTMENT BOARD | 3,600 | 0 | 0 | 0 | For |
| Invesco | 0 | 3,529 | 0 | 0 | Against |
| Renaissance | 3,126 | 0 | 0 | 0 | For |
| Nantahala Capital Management, LLC | 2,870 | 0 | 0 | 0 | For |
| Hudson Bay Capital Management LP | 2,820 | 0 | 0 | 0 | For |
| NEW YORK STATE COMMON RETIREMENT FUND | 2,700 | 0 | 0 | 0 | For |
| Rhumbline | 2,290 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,218 | 0 | 0 | 0 | For |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 2,104 | 0 | 0 | 0 | For |
| SEI | 2,000 | 0 | 0 | 0 | For |
| AQR | 1,820 | 0 | 0 | 0 | For |
| Prudential/PGIM | 1,630 | 0 | 0 | 0 | For |
Institutional-manager reports, all 63 managers: 855,777 for, 18,366 against. Showing the 25 largest; every one is in the interactive database (link above).
99.9% Approved · of votes cast
Description as filed by funds: TO RATIFY THE APPOINTMENT OF GRANT THORNTON ZHITONG CERTIFIED PUBLIC ACCOUNTANTS LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2026.
Gyre Therapeutics, Inc.’s own tally for this item (“3. Ratification of Independent Auditor The appointment of Grant Thornton Zhitong Certified Public Accountants LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026”): 72,487,596 for, 11,626 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3: Ratification of Independent Auditor The appointment of Grant Thornton Zhitong Certified Public Accountants LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 was ratified as follows:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 33 asset managers below reported 1,010,939 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 532,566 | 0 | 0 | 0 | For |
| Fidelity | 182,213 | 0 | 0 | 0 | For |
| BlackRock | 153,546 | 0 | 0 | 0 | For |
| Charles Schwab | 60,096 | 0 | 0 | 0 | For |
| WisdomTree | 20,090 | 0 | 0 | 0 | For |
| Equitable | 16,142 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 9,244 | 0 | 0 | 0 | For |
| Pacific Life | 5,664 | 0 | 0 | 0 | For |
| Global X | 5,633 | 0 | 0 | 0 | For |
| Lincoln Financial | 5,500 | 0 | 0 | 0 | For |
| Northern Trust | 2,500 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 2,488 | 0 | 0 | 0 | For |
| SEI | 2,000 | 0 | 0 | 0 | For |
| ProShares | 1,534 | 0 | 0 | 0 | For |
| Goldman Sachs | 1,469 | 0 | 0 | 0 | For |
| Voya | 1,463 | 0 | 0 | 0 | For |
| GPS Funds I | 1,313 | 0 | 0 | 0 | For |
| Venerable Variable Insurance Trust | 1,124 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 1,063 | 0 | 0 | 0 | For |
| Principal | 887 | 0 | 0 | 0 | For |
| DWS | 880 | 0 | 0 | 0 | For |
| Calvert | 683 | 0 | 0 | 0 | For |
| State Street | 552 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 500 | 0 | 0 | 0 | For |
| American Century | 477 | 0 | 0 | 0 | For |
Showing the 25 largest of 33 asset managers. All 33 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 97,028,322 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 0.55% |
| 2 | Fidelity | 0.19% |
| 3 | BlackRock | 0.16% |
| 4 | Charles Schwab | 0.06% |
| 5 | WisdomTree | 0.02% |
| 6 | Equitable | 0.02% |
| 7 | QUANTITATIVE MASTER SERIES LLC | <0.01% |
| 8 | Pacific Life | <0.01% |
| 9 | Global X | <0.01% |
| 10 | Lincoln Financial | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT, LLC | 0.26% |
| 2 | BlackRock | 0.15% |
| 3 | PNC BANK, NATIONAL ASSOCIATION | 0.10% |
| 4 | State Street | 0.08% |
| 5 | Northern Trust | 0.07% |
| 6 | Charles Schwab | 0.06% |
| 7 | MELLON INVESTMENTS Corp | 0.03% |
| 8 | AllianceBernstein | 0.02% |
| 9 | STRS OHIO | 0.02% |
| 10 | Vanguard | 0.02% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| GNI USA, Inc. | — | 13D |
| Ying Luo | — | 13D |
| Songjiang Ma | — | 13D |
| Vanguard Group | — | 13F |
| BlackRock | — | 13F |
| Geode Capital | — | 13F |
| State Street | — | 13F |
| Charles Schwab | — | 13F |
| Northern Trust | — | 13F |
| Goldman Sachs | — | 13F |
Percentages above are of 97,028,322 shares outstanding, as reported by Gyre Therapeutics, Inc. on its Form 10-Q dated May 1, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Gyre Therapeutics, Inc.’s 10-Q dated May 1, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Gyre Therapeutics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).
proxyvotesnow.com, “Gyre Therapeutics (GYRE) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/gyre-therapeutics-inc/2026 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.